Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.
Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

Agency for Care Effectiveness
Drug guidance

Pembrolizumab for treating high-risk early-stage triple-negative breast cancer

Condition

Breast

Cancer

1 September 2026

Published on 02 Jan 2024
Last Updated on 01 Sep 2026

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended pembrolizumab for inclusion on the MOH List of Subsidised Drugs, for neoadjuvant and adjuvant treatment of previously untreated high-risk, early-stage triple-negative breast cancer. The decision was based on the uncertain extent of clinical benefit and unfavourable cost-effectiveness of pembrolizumab at the price proposed by the company.

Clinical indications, subsidy class and MediShield Life claims eligibility for pembrolizumab are provided in the Annex.

Pembrolizumab for treating high-risk early-stage triple-negative breast cancer (Published 1 Sep 2026) [PDF, 368.19 KB] (opens in new tab)

PES Pembrolizumab for treating high-risk early-stage triple-negative breast cancer (Published 2 Jan 2024) [PDF, 128 KB] (opens in new tab)